248 related articles for article (PubMed ID: 36358967)
1. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
3. Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer.
Luo L; Wang Z; Hu T; Feng Z; Zeng Q; Shu X; Wu A; Huang P; Cao Y; Tu Y; Li Z
Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36545914
[TBL] [Abstract][Full Text] [Related]
4. EZH2 is a potential prognostic predictor of glioma.
Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
[TBL] [Abstract][Full Text] [Related]
5. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
7. circEZH2
Su Z; Zhang M; Luo H; Zhong J; Tan J; Xu Y; Pan X; Zeng H; Nie L; Xu M; Chen N; Chen X; Zhou Q
Cancer Sci; 2023 Apr; 114(4):1378-1395. PubMed ID: 36519785
[TBL] [Abstract][Full Text] [Related]
8. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration.
Fan K; Zhang CL; Zhang BH; Gao MQ; Sun YC
Sci Rep; 2022 Oct; 12(1):16583. PubMed ID: 36195655
[TBL] [Abstract][Full Text] [Related]
10. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
11. Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer.
Yi Y; Li Y; Li C; Wu L; Zhao D; Li F; Fazli L; Wang R; Wang L; Dong X; Zhao W; Chen K; Cao Q
Oncogene; 2022 Mar; 41(11):1610-1621. PubMed ID: 35094010
[TBL] [Abstract][Full Text] [Related]
12. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.
Pan MZ; Song YL; Gao F
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
14. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
16. Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development.
Tao T; Liu D; Liu C; Xu B; Chen S; Yin Y; Ang L; Huang Y; Zhang X; Chen M
Biochim Biophys Acta; 2014 Sep; 1839(9):858-65. PubMed ID: 25017995
[TBL] [Abstract][Full Text] [Related]
17. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.
Sun XB; Chen YW; Yao QS; Chen XH; He M; Chen CB; Yang Y; Gong XX; Huang L
Technol Cancer Res Treat; 2021; 20():1533033821989817. PubMed ID: 33550923
[TBL] [Abstract][Full Text] [Related]
19. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
20. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
Bohrer LR; Chen S; Hallstrom TC; Huang H
Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
